Uric Acid as a Prognostic Factor for Survival Time: A Prospective Cohort Study of Terminally Ill Cancer Patients  Hyun-Sik Shin, MD, Hye-Ree Lee, MD, Duk-Chul Lee, MD, Jae-Yong Shim, MD, Kyung-Hee Cho, MD, Sang-Yeon Suh, MD  Journal of Pain and Symptom Management  Volume 31, Issue 6, Pages 493-501 (June 2006) DOI: 10.1016/j.jpainsymman.2005.11.014 Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 1 Kaplan-Meier survival curves. ∗ indicates “statistically significant”. Graph 1. Survival curve of 118 study subjects (+ marks on the curves-censored subjects). Graph 2. Survival curves of four groups categorized by serum uric acid level: UA1 (<3.2mg/dL, n=28), UA2 (≥3.2 and <4.9mg/dL, n=31), UA3 (≥4.9 and <7.2mg/dL, n=30), and UA4 (≥7.2mg/dL, n=29). UA4 group showed significantly shorter survival time than the other three groups, while there was no significant difference among the UA1, UA2, UA3 groups. P value<0.001 by log-rank test. Graph 3. Survival curves of two groups categorized by serum uric acid level (UA-uric acid), P-value<0.001 by log-rank test. Journal of Pain and Symptom Management 2006 31, 493-501DOI: (10.1016/j.jpainsymman.2005.11.014) Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 2 Variability analysis of serum uric acid levels during the last 3 weeks with repeated measures ANOVA. We defined three intervals as follows: 1 week (0–6 days before death), 2 weeks (7–13 days before death), 3 weeks (14–20 days before death). NS indicates “not significant.” Journal of Pain and Symptom Management 2006 31, 493-501DOI: (10.1016/j.jpainsymman.2005.11.014) Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions